# Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

> **NCT06338683** · PHASE3 · RECRUITING · sponsor: **Qinghai Red Cross Hospital** · enrollment: 230 (estimated)

## Conditions studied

- Advanced Cancer
- Olanzapine
- Progression Free Survival

## Interventions

- **DRUG:** Olanzapine 2.5 MG
- **DRUG:** Standard anti-tumor treatment
- **DIETARY_SUPPLEMENT:** Nutritional advice

## Key facts

- **NCT ID:** NCT06338683
- **Lead sponsor:** Qinghai Red Cross Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-20
- **Primary completion:** 2027-03-20
- **Final completion:** 2028-03-20
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06338683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06338683, "Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06338683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*